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marized with the 3 D’s, which stand for drugs, diets and dila-
tion. Of note, as of yet, there is no EoE-specific drug that has 
been approved by regulatory authorities. This is, among oth-
er reasons, related to the lack of validated outcome mea-
surement instruments until recently. Swallowed topical ste-
roids such as budesonide or fluticasone represent the stan-
dard of care for treating symptomatic pediatric and adult 
EoE patients with inflammatory activity. Several trials have 
already evaluated different biologic therapies, such as anti-
interleukin-5 or anti-IgE. Further studies are on the way. As a 
non-pharmacologic alternative, different dietary regimens 
exist. Dilation can offer long-lasting symptomatic response 
in case of stricturing EoE but does not have any impact on 
the underlying inflammation. This review highlights the lat-
est insights regarding pathophysiology and its impact re-
garding current and future therapeutic strategies. 
 Definition of EoE and Diagnosis 
 The first consecutive case series of patients suffering 
from eosinophilic esophagitis (EoE) were published in 
1993 and 1994 by Attwood et al.  [1] and Straumann et al. 
 [2] . The authors reported on a series of patients charac-
terized by dysphagia and dense esophageal eosinophilic
infiltration. It lasted until 2007 when an international ex-
pert panel published the first guidelines on the diagnosis
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 Abstract 
 Eosinophilic esophagitis (EoE) has been defined as a ‘chron-
ic, immune/antigen-mediated, esophageal disease, charac-
terized clinically by symptoms related to esophageal dys-
function and histologically by eosinophil-predominant in-
flammation’. A peak value of  ≥ 15 eosinophils/high power 
field has been defined as histologic diagnostic cutoff. Other 
conditions associated with esophageal eosinophilia, such as 
gastro-esophageal reflux disease, PPI-responsive esopha-
geal eosinophilia or Crohn’s disease, need to be ruled out 
before EoE can be diagnosed. Males are affected more fre-
quently than females and most of the patients have concom-
itant allergies. Currently, the EoE prevalence is about 1 of 
2,000 inhabitants in Westernized countries. The first EoE pa-
tients were described only 2 decades ago. Despite this short 
period, considerable progress has been made regarding the 
understanding of the pathophysiology, natural history, as-
sessment of disease activity and with respect to evaluating 
different therapeutic options. Untreated EoE can lead to 
esophageal remodeling with reduced compliance and stric-
ture formation, which represents the main risk factor for 
food bolus impactions. The therapeutic options can be sum-
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and therapy of EoE  [3] . In the updated 2011 guidelines, 
EoE was defined by an international expert panel as ‘a 
chronic, immune/antigen-mediated, esophageal disease, 
characterized clinically by symptoms related to esopha-
geal dysfunction and histologically by eosinophil-pre-
dominant inflammation’  [4] . This definition highlights 
the fact that there exists no single test to affirmatively di-
agnose EoE, but that the diagnosis relies rather on a com-
bination of typical symptoms and characteristic histolog-
ic findings. Of note, several differential diagnoses associ-
ated with esophageal eosinophilia have to be excluded 
before EoE can be diagnosed ( table 1 ). EoE patients are 
mostly males and a high prevalence of allergies against 
inhalative or food antigens is observed. Symptoms, most-
ly dysphagia, are typically present already for years before 
EoE diagnosis is established  [5] .
 Epidemiology of EoE 
 Several recently published studies have documented 
that the incidence of EoE is approximately 1 case per 
10,000 inhabitants per year  [6, 7] . In Westernized coun-
tries, a steady increase in incidence of EoE has been ob-
served over the past 2 decades  [5, 6, 8–11] . It has been 
debated whether this observation reflects a true raise in 
incidence of EoE or whether it is, among other things, re-
lated to an enhanced awareness for EoE by gastroenter-
ologists and pathologists. Two population-based studies 
from Switzerland, one in the German speaking and one 
in the French speaking part, have shown that indeed EoE 
incidence and cumulative prevalence increases much 
stronger than the rate of annual upper endoscopies that 
was performed during the observation period  [5, 12] . 
This finding speaks in favor of an increase in incidence 
and prevalence that is beyond the one that could be ex-
plained only by enhanced awareness for EoE by gastroen-
terologists and pathologists.
 EoE prevalence in 2009 in the German speaking part 
of Switzerland was reported to be 42.8 per 100,000 per-
sons, corresponding to 1 EoE patient in 2,336 inhabit-
ants. These prevalence data compare well with the data 
from Dellon et al. [13] who evaluated the EoE prevalence 
in the United States to be 56.7 per 100,000 persons. In 
summary, we are confronted with an increasing inci-
dence and cumulative prevalence of EoE in Westernized 
countries.
 Up to 80% of EoE patients have concomitant atopic 
diseases and the majority of them has allergies against 
food antigens and/or aeroallergens as defined by skin 
prick and/or allergen-specific IgE tests  [14] . Allergen 
avoidance by dietary measures is successfully used in the 
treatment of EoE  [15–17] . Based on findings from con-
trolled food reintroduction, milk and wheat have been 
identified as the leading causative food categories  [17] .
 Pathophysiology 
 The pathogenesis of EoE is still incompletely under-
stood. It is generally accepted that it results from a com-
plex interplay between genetic, environmental and host 
immune system factors. The esophagus is normally de-
void of eosinophils; as such the finding of esophageal eo-
sinophils denotes an underlying pathology, such as EoE 
or gastro-esophageal reflux disease (GERD)  [18] .
 An overview of the pathogenesis is provided in  figure 
1 . Several groups found esophageal barrier defects that 
might facilitate the entry of food allergens or swallowed 
aero-allergens. Rothenberg and colleagues focused on 
cadherins, a group of junctional proteins within the des-
mosomes, in particular, on the adhesion molecule des-
moglein-1 (DSG1)  [19] . They found that DSG1 is >20 
times downregulated in active EoE compared to controls 
and that DSG1 deficiency leads to a structural alteration 
of the mucosa. Another group found that in children with 
active EoE, the expression of the intercellular junction 
proteins E-cadherin and claudin-1 is reduced  [20] . Obvi-
ously, in active EoE, the mucosal integrity is altered due 
to defects in desmosomal and tight junction adhesion 
proteins. Interestingly, functional defects in desmosomes 
are reversed by successful treatment of EoE, and the func-
Table 1.  Differential diagnosis of esophageal eosinophilia
Diseases associated with esophageal eosinophilia
EoE
GERD
PPI-responsive esophageal eosinophilia
Eosinophilic gastrointestinal diseases
Esophageal infections (e.g., fungal, viral, parasitic)
Crohn’s disease
Celiac disease
Achalasia
Hypereosinophilic syndrome
Pemphigus
Vasculitis
Drug hypersensitivity
Connective tissue diseases
Graft vs. host disease
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tion of the mucosal barrier of patients having remittent 
EoE and of healthy controls is almost comparable  [19] . 
These findings speak in favor of the fact that disturbed 
mucosal integrity in EoE is the result, and not the cause, 
of the chronic eosinophil inflammation.
 Antigenic proteins, which are typically derived from 
food and less frequently from inhaled proteins, trigger an 
adaptive T helper 2 (Th2) cell-mediated response that 
produces a set of different cytokines, such as interleukin 
(IL)-5 and IL-13. IL-13 subsequently triggers esophageal 
resident cells such as the epithelial cells to produce a large 
set of proteins. Thymic stromal lymphopoietin (TSLP) 
promotes dendritic cell-mediated Th2 differentiation 
while tumor necrosis factor alpha (TNF-alpha) increases 
adhesion molecules on endothelial cells. The protein eo-
taxin-3 is strongly expressed by the esophageal epitheli-
um and recruits eosinophils from the peripheral blood 
into the tissue  [21] . Antigen-driven Th2 cells also pro-
duce IL-5, which activates eosinophils and enhances their 
responsiveness to eotaxin-3 and prolongs also their cel-
lular survival. Eosinophils, T-cells and mast cells are ele-
vated in esophageal mucosal biopsies with T-cells being 
polarized toward a Th2 immunity  [22] . A recent publica-
tion highlighted a role for IgG4 in EoE pathogenesis  [23] . 
The production of transforming growth factor beta (TGF-
beta) by eosinophils leads to subepithelial fibrosis  [24] .
 Natural History of EoE 
 Straumann et al. [5] were the first to address, in 2006, 
EoE’s natural history by reporting on a prospective case 
series of 30 adult patients with a mean of a 7.2 years follow-
up period. Patients were not under any anti-eosinophil 
 Fig. 1. Simplified immunopathogenesis of EoE. EoE is probably 
triggered by food allergens and aeroallergens. Epithelial barrier de-
fects might facilitate the entry of allergens into the esophageal ep-
ithelium. Dendritic cells process allergens and produce, among 
other cytokines, TNF-alpha which increases adhesion molecules 
on endothelial cells. The esophageal epithelium produces TSLP 
that promotes dendritic-cell mediated Th2 differentiation. Eotax-
in-3, which is expressed by the esophageal epithelium, attracts eo-
sinophils. IL-13 promotes B-cells to produce IgE and IgG4. IL-9 
activates mast cells that bind IgE. IL-5 promotes eosinophil matu-
ration in the bone marrow and activates eosinophils. Eosinophils 
express TGF-beta which stimulates fibroblasts to produce extra-
cellular matrix proteins. 
B cell
T cell
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treatment nor were they treated with elimination diets 
during their follow-up. Dysphagia as well as eosinophilic 
esophageal infiltrations persisted over time. In addition, 
authors noted the development of subepithelial fibrosis 
over time  [5] . The first data on the natural history of pedi-
atric EoE patients was published in 2007 and evaluated 89 
pediatric EoE patients over an 8-year follow-up period 
 [25] . EoE was found to be a chronic and relapsing condi-
tion, associated with atopy  [25] . A retrospective study
from Mayo Clinic Rochester among 32 adult EoE patients 
revealed that over a mean follow-up duration of 3.3 years,
91% of patients reported recurrent symptoms whereas
61% of patients repeated treatment with swallowed topical 
corticosteroids at least once  [26] . A retrospective and pro-
spective chart review of 620 EoE patients (whereof 330
patients had a follow-up period >1 year for analysis) at the 
Children’s hospital of Philadelphia showed that EoE is a
chronic disease and that <10% of patients developed toler-
ance to their food allergies  [27] . A prospective study eval-
uating the role of epithelial mesenchymal transition
(EMT) in 17 EoE patients, 15 patients with indeterminate
EoE, 7 patients with GERD and 21 persons with normal
esophagus showed that EMT likely contributed to subep-
ithelial fibrosis in EoE patients and that it resolved under
treatment that decreased esophageal inflammation  [28] . 
Furthermore, the EMT resolution correlated with de-
creased numbers of esophageal eosinophils  [28] .
 A retrospective study in 200 adult EoE patients from 
Switzerland found that with increasing duration of delay 
in diagnosis, the prevalence of fibrotic esophageal fea-
tures increased from 46.5% (diagnostic delay 0–2 years) 
to 87.5% (diagnostic delay, >20 years)  [29] . Similarly, the 
prevalence of esophageal strictures (defined as esopha-
geal diameter of  ≤ 10 mm) increased with duration of di-
agnostic delay, from 17.2% (diagnostic delay 0–2 years) 
to 70.8% (diagnostic delay, >20 years, p  < 0.001). The 
length of diagnostic delay was identified as the only risk 
factor for strictures at the time of EoE diagnosis  [29] . The 
findings from the Swiss EoE cohort were recently cor-
roborated by a retrospective study in 64 adult EoE pa-
tients from Tampa, Florida  [30] . A significant difference 
in mean time of delayed diagnosis in patients with <10 
mm esophageal diameter (14.8 years) was found when 
compared to patients with an esophageal diameter of  ≥ 17 
mm (5 years, p = 0.006). These findings are in line with 
the results of a retrospective study in 379 adult EoE pa-
tients from University of North Carolina, Chapel Hill, 
that aimed to evaluate the clinical features of EoE patients 
with predefined phenotypes and to determine predictors 
of these phenotypes  [31] . For each 10-year increase in age 
an odds ratio for fibrostenosis of 2.1 was identified. These 
findings suggested that the natural history of EoE repre-
sents a progression from an inflammatory to a fibroste-
notic phenotype  [31] . The natural history of untreated 
EoE is not only characterized by morphologic alterations 
such as esophageal strictures and histologically subepi-
thelial fibrosis, but also functional abnormalities of 
esophageal motility  [32] .
 Therapeutic Options 
 The therapy options can be summarized as the 3 D’s, 
which stands for drugs, diet and dilation.
 For an in-depth review of therapy recommendations, 
we kindly refer to the ACG guidelines  [33] . Dietary ther-
apy is effective as first-line treatment to induce histologic 
and clinical response and/or remission of EoE in pediatric 
and adult patients  [16, 33–34] . Dietary therapy is based 
on the fact that the majority of EoE patients has food al-
lergies that might contribute to EoE pathogenesis. It of-
fers the advantage of a non-pharmacologic treatment 
strategy and can be successfully used in the long-term run 
 [35] . There exist 3 types of diets: an aminoacid-based for-
mula diet, a targeted elimination diet (which is based on
the results of skin testing and serum IgE levels) and the
empiric elimination diet. In the empiric elimination diet,
the most frequently offending food categories are avoided 
(milk, wheat, eggs, soy, seafood, nuts). The identification
of the offending food(s) is performed based on selective
re-introduction of foods with endoscopic and histologic
control  [33] .
 The following pharmacologic treatment options exist 
for EoE: acid suppression, swallowed topical glucocorti-
coids such as budesonide, fluticasone propionate, cicle-
sonide and, rarely necessary, systemic steroids. In addi-
tion, several biologic therapies have been evaluated.
 GERD may mimic EoE, it may coexist with it or con-
tribute to it  [36] . On the other hand, EoE can also con-
tribute to GERD as it may impact the esophageal clear-
ance  [37] . EoE diagnosis is based on the persistence of 
esophageal eosinophilia despite a 2-month treatment 
with PPI or a normal pH-metric study  [33] . EoE patients 
may profit from PPI therapy by reducing acid production 
in patients with coexistent GERD, or by PPI-inherent an-
ti-eosinophil mechanisms  [38] . PPI therapy may also be 
helpful in patients with established EoE as the altered 
esophagus may be predisposed and more sensitive to 
physiologic acid exposure  [39] . About one-third of pa-
tients with clinical, endoscopic and histologic features 
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compatible with EoE will show a clinical and histologic 
response to PPI treatment  [33, 40] . These patients suffer 
from so-called ‘PPI-responsive esophageal eosinophilia’ 
and may be treated on a long-term basis by acid suppres-
sion  [33] .
 As of yet, no anti-inflammatory drug has been ap-
proved by regulatory authorities specifically for EoE 
treatment. Swallowed topical budesonide and fluticasone 
propionate have consistently shown to effectively reduce 
esophageal eosinophil counts  [41–44] . However, an im-
provement in dysphagia has not been consistently shown 
under swallowed topical steroids  [41–44] . This observa-
tion might be related to the use of non-validated instru-
ments for EoE symptom assessment or dietary modifica-
tions that might have resulted in a higher placebo re-
sponse rate  [45] . In fact, validated instruments to assess 
clinical EoE activity have become available only recently 
 [46] . One trial with 4 children evaluated ciclesonide, a
topical glucocorticoid with less systemic absorption than
fluticasone and showed that symptoms as well as eosino-
phil counts significantly decreased after 2 months of
treatment  [47] .
 Systemic steroids are rarely used in EoE given their 
side effect profile and the generally high efficacy of topical 
swallowed steroids. One randomized trial evaluated oral 
prednisolone with swallowed topical fluticasone  [48] . At 
week 4, almost all patients, irrespective of the treatment 
group, were free of symptoms whereas histologic im-
provement was noted to be greater in the prednisone 
group. As expected, glucocorticoid side effects were more 
frequently observed in the prednisone group when com-
pared to the fluticasone group  [48] .
 Several other treatment options have been evaluated 
for EoE. The leukotriene inhibitor, montelukast, reduced 
symptoms in one study but had no effect on esophageal 
eosinophil counts  [49] . In another study, montelukast 
was inefficient in maintaining steroid-induced clinical 
and histologic remission  [50] . One case series with 3 pa-
tients documented a clinical and histologic response on 
azathioprine or 6-mercaptopurine in steroid-dependent 
EoE patients  [51] . In addition, several trials evaluated bi-
ologic therapies with targeted molecules. In 3 adult pa-
tients with glucocorticoid-dependent EoE, infliximab 
was not effective at resolving symptoms or esophageal eo-
sinophilia ( fig.  1 )  [52] . Mepolizumab is a humanized 
monoclonal antibody against IL-5, which has a key role 
in the recruitment of eosinophils ( fig. 1 ). A placebo-con-
trolled trial found a reduction of esophageal eosinophils 
in mepolizumab-treated patients when compared to pa-
tients treated with placebo, however in clinical terms, 
there was no statistically significant improvement  [53] . 
Another study that evaluated 3 different doses of mepo-
lizumab in pediatric EoE patients found a significant de-
crease in esophageal eosinophil counts and improvement 
in endoscopic findings in all 3 groups  [54] . However, 
symptoms did not improve. Reslizumab, an IL-5 neutral-
izing antibody, was tested in 226 children and adolescents 
with EoE ( fig. 1 )  [55] . Patients treated with reslizumab 
experienced a significant reduction in esophageal eosino-
phil counts when compared to placebo. However, there 
was no significant difference to the placebo group with 
regard to the change of symptoms  [55] . Omalizumab, an 
anti-IgE antibody ( fig. 1 ), was used in 2 patients with mul-
tiple food allergies and EoE. Omalizumab treatment im-
proved allergic symptoms, but not endoscopic or histo-
logic features of EoE  [56] . There is one study evaluating 
an oral prostaglandin D2 receptor antagonist (OC000459). 
In a randomized trial, 26 adult patients with steroid-de-
pendent or steroid-refractory EoE were randomized to 
either receive OC000459 or placebo. At week 8, OC000459 
but not placebo was associated with a significant reduc-
tion in esophageal eosinophil counts and an improve-
ment in symptoms  [57] .
 In case of stricturing disease, esophageal dilation either 
by through-the-scope balloons or by Savary bougies can 
lead to long-lasting symptom improvement  [58] . A re-
cently published meta-analysis evaluated the efficacy and 
safety of esophageal dilation of 9 studies that included 525 
patients who underwent a total of 992 esophageal dilations 
 [59] . A total of 3 perforations and 1 hemorrhage were not-
ed. Six studies reported post-procedural chest pain in 2%
of patients. Clinical improvement from dilation was noted 
in 75% of patients. As such, esophageal dilation can be re-
garded as a safe procedure with a low rate of serious com-
plications (<1%). Furthermore, esophageal dilation can
lead to symptom improvement in the majority of treated
patients. One drawback is that esophageal dilation does
not influence the underlying eosinophilic esophageal in-
flammation. Lipka et al. [60] recently reported on a cohort 
of 13 adult EoE patients with a mean follow-up of 13.6
years that were treated by PPI and esophageal dilation
once every 2 years. Authors concluded that this strategy
appeared to be a safe long-term treatment.
 In summary, despite the fact that the first EoE patients 
have been described only a little >20 years ago, consider-
able progress has been made in evaluating different treat-
ment options as well as in understanding the pathophys-
iology and the natural history. As of yet, there is no drug 
on the market to specifically treat EoE that has an ap-
proval from regulatory authorities. The current treat-
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ment options have some inherent limitations. As such, 
the concerted effort of different stakeholders will be nec-
essary to continue the endeavor of providing our patients 
with much-needed therapies.
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